Why ORMP Stock dropped -2.84% Today — RQD Quant Desk Flash

Per the Roarable RQD rating, ORMP carries an RQD Score of 41 and a letter grade of D-, with the verdict "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are scored as follows:

• Fundamental cash engine: 6 / 20 (ROIC -7.8%; FCF yield -5.2%). This is the weakest pillar relative to its weight, reflecting negative returns on invested capital and negative free-cash-flow yield.
• Whale 13F flow: 12 / 20 (institutional accumulation and options positioning). This is a moderate score; the source data does not itemize the underlying holdings (see Analyst View section).
• Insider conviction: 3 / 20 (SEC Form 4 and Congressional PTR cluster flow). This is the lowest pillar score, indicating limited insider-conviction signals in the rating inputs.
• Macro regime fit: 10 / 20 (Beta 1.0; sector sensitivity). A beta of 1.0 implies market-level sensitivity per the market data section.
• Forensic balance sheet: 10 / 20 (Altman Z 2.5; Piotroski F 3/9; Debt/Equity 0.5). The Altman Z-Score and Piotroski F-Score are mid-to-weak, and the Debt/Equity figure is reported as 0.5.

For a prospective investor, the upside case rests on the balance sheet and institutional interest, while the downside is concentrated in the cash-generation and insider-conviction pillars. Negative ROIC and negative FCF yield mean the company is not currently converting invested capital or operations into free cash flow, so valuation depends on factors outside current cash generation. The mid-range balance-sheet scores suggest liquidity is not the immediate concern, but the trajectory of cash burn is central to evaluating the stock today. This is an analytical framing, not personalized advice.

Per the profile, Oramed Pharmaceuticals Inc. (ORMP) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. The source data does not describe specific products, customers, or the company's revenue model. Reported revenue in the SEC financials is $2.0M for FY 2025, $0.0M for FY 2024, and $1.3M for FY 2023. Market capitalization is listed as $0.2B in the profile and $176.0M in market data.

Per the market data, gross margin is 0.7%, operating margin is -60%, and net margin is 3.8%. ROIC is -7.8% and FCF yield is -5.2%. Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 3/9, and Debt/Equity is 0.5. Reported cash declined from $54.4M (FY 2024) to $45.9M (FY 2025) while operating losses persisted across all three periods.

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be assessed from the provided data beyond the sector classification (Health Care) and industry classification (Biotechnology: Pharmaceutical Preparations). A prospective investor should note that the absence of mapped links means this analysis cannot identify ripple effects from this graph.

• What specific products or pipeline assets generate the reported $2.0M FY 2025 revenue, and what is the revenue trajectory?
• What are the company's total debt and EPS figures, given that these fields are reported as N/A in the financials?
• What is the cash runway implied by $45.9M in cash against FY 2025 free cash flow of $-9.2M?
• Does the November 12 results date carry any scheduled catalysts, and what is the consensus expectation?
• Who are the institutional and insider holders, given that the holders section is empty?